The results of the trial demonstrated that Resminostat monotherapy showed substantial anti-tumour activity, including complete and partial tumour responses.
Furthermore, the study demonstrated that the drug was safe and well tolerated in the advanced stage patient population.
The overall response rate (ORR) of 33.3% together with the clinical benefit recorded in total for 54.5% of the patients shows the substantial anti-tumour activity of resminostat monotherapy in an advanced and heavily pre-treated Hodgkin’s Lymphoma patient population.